Your session is about to expire
← Back to Search
Lenalidomide + Ibrutinib for Lymphoma
Study Summary
This trial is testing the side effects and best dose of lenalidomide and ibrutinib for patients with B-cell non-Hodgkin lymphoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 1 & 2 trial • 24 Patients • NCT03010358Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I need medication to prevent blood clots.I do not have any uncontrolled illnesses or social situations that could affect my participation.I am allergic to lenalidomide or similar drugs.I haven't had any infections needing treatment recently.I am not on any immune-suppressing drugs except for corticosteroids.All possible curative treatments have been tried or are not suitable for me.I have not received any live vaccines recently.I have had at least one treatment before, including a stem cell transplant.I have not had chemotherapy or radiotherapy recently.My lymphoma has spread to my brain or spinal cord.I can take care of myself but might not be able to do active work.I have been treated with a BTK inhibitor before.My lymphoma is a specific type of B-cell non-Hodgkin's.You have ongoing hepatitis B or C infection.I am 18 years old or older.I have not had major or minor surgery recently.You have HIV and meet certain conditions.I have no lasting side effects from previous cancer treatments.You are expected to live for at least 12 weeks.I cannot swallow pills or have major digestive issues.I have a bleeding disorder or hemophilia.I am taking medication that strongly affects liver enzymes.My organs and bone marrow work well without needing extra help.I am not taking any medications known to cause heart rhythm problems.I have a serious liver condition.I need to take 20 mg or more of corticosteroids daily.
- Group 1: Treatment (lenalidomide, ibrutinib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What afflictions is Pharmacological Study mainly applied to?
"Pharmacological Study has demonstrated efficacy in amyloidosis and other disease-states such as lymphoma, refractory diffuse large b cell lymphoma (dlbcl), and muscular dystrophy."
To what extent is this trial being populated by volunteers?
"This research project is no longer seeking participants. It was first posted on September 13th 2013 and underwent its last update on July 28th 2022. Alternatively, there are 2718 studies actively recruiting those with lymphoma or large b-cell diffuses as well as 412 Pharmacological Studies accepting enrollees currently."
What is the main goal of this experiment?
"This medical study, taking place over a two year period, aims to determine the maximum tolerated dose. Secondary goals include measuring overall response duration through descriptive statistics and assessing degree of response by utilizing International Harmonization Project Lymphoma Response Criteria as well as Waldenstrom's Macroglobulinemia Response criteria while also summarizing data on stable disease duration."
Can you provide information about prior investigations involving Pharmacological Study?
"Currently, 412 trials researching Pharmacological Study are being conducted. Of those studies, 79 have reached the third stage of clinical development. Most of these investigations can be found in Chicago, Illinois; however there are 20383 other locations running related experiments."
Are individuals currently being accepted into the experiment?
"This trial is no longer actively recruiting participants. The posting was first published on September 13th 2013 and most recently updated on July 28th 2022. If you are searching for other studies, there are 2718 clinical trials in search of patients with lymphoma, large b-cell diffuse and 412 Pharmacological Studies currently enrolling volunteers."
Has the FDA approved this pharmaceutical research?
"With limited safety and efficacy data, the risk associated with this clinical trial scored a 1 on our assessment scale."
Share this study with friends
Copy Link
Messenger